IP Library Granted Patent US 10,457,695
Granted Patent B2
US 10,457,695 · App. 16/070,002 · Granted Oct 29, 2019

Process for the preparation of tavaborole

Inventors: Srinivasan Subramanian Kuduva (Navi Mumbai, IN); Rajender (Telangana, IN); Mahendra Joma Choraghe (Navi Mumbai, IN); Samir Naik (Thane, IN); Shekhar Bhaskar Bhirud (Mumbai, IN)
Assignee: Glenmark Life Sciences Limited
C07F5/025A61K31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,457,695
App. No.
16/070,002
Granted
Oct 29, 2019
Kind
B2
Abstract

The present invention relates to process for preparation of tavaborole with high purity. The present invention relates to method of assessing the purity of tavaborole.

Claims (26)

1. A process for the preparation of tavaborole, a compound of formula I, comprising:

a) reacting 2-halo-5-fluorotoluene, a compound of formula II

with a borate ester to obtain 2-methyl-4-fluorophenylboronic acid, a compound of formula III, wherein X is a halogen selected from chloro, bromo or iodo;

b) converting the compound of formula III to 2-halomethyl-4-fluorophenylboronic acid, a compound of formula IV

in the presence of mixture of halogenating agents; and

c) cyclizing the compound of formula IV to obtain tavaborole.

2. The process as claimed in claim 1 , wherein in step b) the mixture of halogenating agents is a mixture of brominating agents.

3. The process as claimed in claim 2 , wherein in step b) the mixture of brominating agents comprises bromine and N-bromosucciminide.

4. The process as claimed in claim 3 , wherein bromine is used in catalytic amount to the amount of N-bromosuccinimide.

5. The process as claimed in claim 1 , wherein in step b) halogenation is carried out in the presence of a radical initiator.

6. The process as claimed in claim 1 , further comprising isolating tavaborole from a mixture of water and an organic solvent selected from the group consisting of C 1-4 alcohols, ethers, amides, esters, nitriles, sulfoxides, ketones, hydrocarbons and halogenated hydrocarbons and mixtures thereof.

7. The process as claimed in claim 6 , wherein the isolating comprises:

a) dissolving tavaborole in a solvent selected from the group consisting of C 1-4 alcohols, ethers, amides, esters, nitriles, sulfoxides, ketones, hydrocarbons and halogenated hydrocarbons and mixtures thereof to obtain a solution;

b) adding water as an anti-solvent to the above solution; and

c) isolating tavaborole from the above step (b).

8. The process as claimed in claim 6 , wherein the isolation comprises isolating from a mixture of C 1-4 alcohol and water solvent.

9. The process as claimed in claim 8 , wherein a level of the compound of formula V and/or the level of compound of formula XIV

is less than 0.5% w/w with respect to the obtained tavaborole as determined by HPLC.

10. A method for preparing tavaborole, comprising the steps of:

(a) providing a batch of tavaborole or a salt thereof thereof prepared by the process as claimed in claim 1 ;

(b) assessing the purity of said batch of tavaborole, by using a compound of formula V or a compound of formula XIV as a reference marker to determine the level of the compound of formula V or the compound of formula XIV

and

(c) selecting the batch of tavaborole only if the % of the compound of formula V or the % of the compound of formula XIV is less than 0.15% w/w as determined by HPLC.

11. A method for preparing tavaborole thereof as prepared by the process as claimed in claim 1 , further comprising the steps of:

(a) providing a standard solution of compound V or compound XIV

(b) using the standard solution as a reference marker to determine a level of the compound of formula V or the compound of formula XIV in tavaborole.

Assignments (3)
CHANGE OF NAME Recorded Jan 7, 2025
From: GLENMARK LIFE SCIENCES LIMITED
To: ALIVUS LIFE SCIENCES LIMITED
Reel/Frame 069775/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2019
From: KUDUVA, SRINIVASAN SUBRAMANIAM; -, RAJENDER; CHORAGHE, MAHENDRA JOMA; NAIK, SAMIR; BHIRUD, SHEKHAR BHASKAR
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 048735/0699 →
Priority Claims (1)
IN 201621001791 · Jan 18, 2016 · national
Continuity (1)
Related Publication 20190023724A1 · Jan 24, 2019